Life Sciences Law & Industry Report connects the dots among the many disciplines that make up the burgeoning life sciences industry, with biweekly updates on current regulatory, legislative,...
Nov. 12 — A new biomarker to detect an infection caused by a common mold has been approved by the FDA for enrolling patients into drug studies, according to a guidance released Nov. 13.
The Food and Drug Administration's document, “Guidance on Qualification of Biomarker—Galactomannan in Studies of Treatments of Invasive Aspergillosis,” finalizes a draft guidance issued more than a year ago (79 Fed. Reg. 63,921, Oct. 27, 2014).
Janet Woodcock, director of the FDA's drug center, has said there's a need to develop evidentiary standards for biomarkers that can be integrated into drug development. The development of more qualifying biomarkers will be especially critical for precision medicine, which uses biomarkers to determine which patients are more likely to benefit from these targeted treatments.
With the guidance, drug developers can use the biomarker for “context of use,” an FDA term for a statement that describes “the manner of use, interpretation, and purpose of use of a biomarker in drug development.” Drug companies can now submit investigational new drug applications, new drug applications and biologics license applications without the FDA's Center for Drug Evaluation and Research having to review the biomarker to reconsider and reconfirm its suitability every time.
According to a Nov. 13 Federal Register notice announcing its availability (80 Fed. Reg. 70,235), the guidance provides a “qualified context of use (COU) for Galactomannan detection in serum and/or bronchoalveolar lavage (BAL) fluid as the sole microbiological criterion to classify patients as having probable invasive Aspergillosis (IA) for enrollment in clinical trials.”
The guidance also describes the conditions and constraints for which CDER determined this biomarker was acceptable under the agency's biomarker qualification program.
According to the Centers for Disease Control and Prevention, aspergillosis is caused by a common mold that can cause health problems in people with weakened immune systems or lung diseases, such as allergic reactions, lung infections and infections in other organs. Galactomannan is a molecule found in the cell wall of aspergillus species, Mayo Medical Laboratories explained.
The FDA approved a qualified infectious disease product designation—an expedited drug approval mechanism—in August for an antifungal drug to treat invasive aspergillosis.
Submit comments by Jan. 12, 2016, electronically to http://www.regulations.gov or in writing to Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Room 1061, Rockville, Md. 20852. All comments should included Docket No. FDA-2013-D-1630.
For more information, contact Marianne Noone, Center for Drug Evaluation and Research (Office of Translational Sciences, Immediate Office), Food and Drug Administration, 10903 New Hampshire Ave., Building 21, Room 4528, Silver Spring, Md. 20993-0002, (301) 796-2600.
To contact the reporter on this story: Jeannie Baumann in Washington at email@example.com
To contact the editor responsible for this story: Lee Barnes at firstname.lastname@example.org
The guidance is available at http://src.bna.com/3w.
The Federal Register notice is at http://www.gpo.gov/fdsys/pkg/FR-2015-11-13/html/2015-28804.htm.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)